This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Email citation

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2009 Dec 16;302(23):2593-4.

doi: 10.1001/jama.2009.1863.

Late-life dementias: does this unyielding global challenge require a broader view?

Thomas J Montine, Eric B Larson

PMID: 20009062
PMCID: PMC2827770
DOI: 10.1001/jama.2009.1863

Editorial

Late-life dementias: does this unyielding global challenge require a broader view?

Thomas J Montine et al. JAMA. 2009.

. 2009 Dec 16;302(23):2593-4.

doi: 10.1001/jama.2009.1863.

Authors

Thomas J Montine, Eric B Larson

PMID: 20009062
PMCID: PMC2827770
DOI: 10.1001/jama.2009.1863

No abstract available

PubMed Disclaimer

Comment on

Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial.
Green RC, Schneider LS, Amato DA, Beelen AP, Wilcock G, Swabb EA, Zavitz KH; Tarenflurbil Phase 3 Study Group. Green RC, et al. JAMA. 2009 Dec 16;302(23):2557-64. doi: 10.1001/jama.2009.1866. JAMA. 2009. PMID: 20009055 Free PMC article. Clinical Trial.
Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging.
Lieb W, Beiser AS, Vasan RS, Tan ZS, Au R, Harris TB, Roubenoff R, Auerbach S, DeCarli C, Wolf PA, Seshadri S. Lieb W, et al. JAMA. 2009 Dec 16;302(23):2565-72. doi: 10.1001/jama.2009.1836. JAMA. 2009. PMID: 20009056 Free PMC article.

Similar articles

Tarenflurbil: a shot on goal.
Aisen PS. Aisen PS. Lancet Neurol. 2008 Jun;7(6):468-9. doi: 10.1016/S1474-4422(08)70091-7. Epub 2008 Apr 29. Lancet Neurol. 2008. PMID: 18450518 No abstract available.
[Progress in the development of anti-amyloid drugs for treatment of Alzheimer's disease.].
Shitaka Y, Mitani Y, Nagakura A, Miyake A, Matsuoka N. Shitaka Y, et al. Nihon Yakurigaku Zasshi. 2010 Jul;136(1):15-20. doi: 10.1254/fpj.136.15. Nihon Yakurigaku Zasshi. 2010. PMID: 20628208 Review. Japanese. No abstract available.
Targeting nascent soluble Aβ42 for potential Alzheimer drug development.
Zhang M, Hausmann L, Song W. Zhang M, et al. J Neurochem. 2013 May;125(3):329-31. doi: 10.1111/jnc.12156. Epub 2013 Feb 13. J Neurochem. 2013. PMID: 23405973 No abstract available.
[Gamma-secretase inhibitors and modulators].
Iwai A. Iwai A. Nihon Rinsho. 2011 Dec;69 Suppl 10 Pt 2:83-7. Nihon Rinsho. 2011. PMID: 22755160 Review. Japanese. No abstract available.
CHF5074, a novel gamma-secretase modulator, attenuates brain beta-amyloid pathology and learning deficit in a mouse model of Alzheimer's disease.
Imbimbo BP, Hutter-Paier B, Villetti G, Facchinetti F, Cenacchi V, Volta R, Lanzillotta A, Pizzi M, Windisch M. Imbimbo BP, et al. Br J Pharmacol. 2009 Mar;156(6):982-93. doi: 10.1111/j.1476-5381.2008.00097.x. Br J Pharmacol. 2009. PMID: 19239474 Free PMC article.

See all similar articles

Cited by

Leveraging neuropathological data in pharmacoepidemiology: A promising approach for dementia prevention?
Marcum ZA, Keene CD, Larson EB. Marcum ZA, et al. Pharmacoepidemiol Drug Saf. 2021 Jan;30(1):1-3. doi: 10.1002/pds.5068. Epub 2020 Jun 29. Pharmacoepidemiol Drug Saf. 2021. PMID: 32602137 Free PMC article. No abstract available.
Proposal Guidelines for Standardized Operating Procedures of Brain Autopsy: Brain Bank in South Korea.
Lee KH, Seo SW, Lim TS, Kim EJ, Kim BC, Kim Y, Lee HW, Jeon JP, Shim SM, Na DL, Huh GY, Lee MC, Suh YL. Lee KH, et al. Yonsei Med J. 2017 Sep;58(5):1055-1060. doi: 10.3349/ymj.2017.58.5.1055. Yonsei Med J. 2017. PMID: 28792154 Free PMC article.
Recent Progress in Alzheimer's Disease Research, Part 3: Diagnosis and Treatment.
Hane FT, Robinson M, Lee BY, Bai O, Leonenko Z, Albert MS. Hane FT, et al. J Alzheimers Dis. 2017;57(3):645-665. doi: 10.3233/JAD-160907. J Alzheimers Dis. 2017. PMID: 28269772 Free PMC article. Review.
Somatic comorbidities and Alzheimer's disease treatment.
Clodomiro A, Gareri P, Puccio G, Frangipane F, Lacava R, Castagna A, Manfredi VG, Colao R, Bruni AC. Clodomiro A, et al. Neurol Sci. 2013 Sep;34(9):1581-9. doi: 10.1007/s10072-013-1290-3. Epub 2013 Feb 1. Neurol Sci. 2013. PMID: 23370896 Free PMC article.
The advantages of frontotemporal degeneration drug development (part 2 of frontotemporal degeneration: the next therapeutic frontier).
Boxer AL, Gold M, Huey E, Hu WT, Rosen H, Kramer J, Gao FB, Burton EA, Chow T, Kao A, Leavitt BR, Lamb B, Grether M, Knopman D, Cairns NJ, Mackenzie IR, Mitic L, Roberson ED, Van Kammen D, Cantillon M, Zahs K, Jackson G, Salloway S, Morris J, Tong G, Feldman H, Fillit H, Dickinson S, Khachaturian ZS, Sutherland M, Abushakra S, Lewcock J, Farese R, Kenet RO, Laferla F, Perrin S, Whitaker S, Honig L, Mesulam MM, Boeve B, Grossman M, Miller BL, Cummings JL. Boxer AL, et al. Alzheimers Dement. 2013 Mar;9(2):189-98. doi: 10.1016/j.jalz.2012.03.003. Epub 2012 Oct 10. Alzheimers Dement. 2013. PMID: 23062850 Free PMC article. Review.

See all "Cited by" articles

References

1. Christensen K, Doblhammer G, Rau R, Vaupel JW. Aging populations: the challenges ahead. Lancet. 2009;374(9696):1196–1208. - PMC - PubMed
1. Graves AB, Larson EB, Edland SD, et al. Prevalence of dementia and its subtypes in the Japanese American population for King County Washington State: the Kame Project. Am J Epidemiol. 1996;144(8):760–771. - PubMed
1. Green RC, Schneider LS, Amato DA, et al. Tarenflurbil Phase 3 Study Group Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA. 2009;302(23):2557–2564. - PMC - PubMed
1. Lieb W, Beiser AS, Vasan RS, et al. Association of plasma leptin levels with incident Alzheimer disease and MRI measures of brain aging. JAMA. 2009;302(23):2565–2572. - PMC - PubMed
1. Selkoe DJ. Soluble oligomers of the amyloid beta-protein impair synaptic plasticity and behavior. Behav Brain Res. 2008;192(1):106–113. - PMC - PubMed

Publication types

Actions
Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Grants and funding

P50 AG005136-229003/AG/NIA NIH HHS/United States

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information